Azilsartan ameliorates ox-LDL-induced endothelial dysfunction via promoting the expression of KLF2

Related Experiment Video

Updated: Nov 6, 2025

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
06:09

Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly

Published on: August 20, 2019

16.2K

Wenfeng Li1,2, Chenggao Wang2, Dandan Zhang2

  • 1Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou 510630, Guangdong, China.

Aging
|May 4, 2021
PubMed

Insights

Azilsartan protects against oxidized LDL-induced endothelial dysfunction by increasing Krüppel-like factor 2 (KLF2) expression. This mechanism helps restore nitric oxide production and reduce inflammation in cardiovascular disease models.

Area of Science:

  • Cardiovascular Research
  • Endothelial Biology
  • Pharmacology

Background:

  • Oxidized LDL (ox-LDL) contributes to cardiovascular diseases like atherosclerosis by causing endothelial dysfunction.
  • Azilsartan, an angiotensin II receptor blocker, is used to treat hypertension.
  • The potential protective effects of Azilsartan against ox-LDL-induced endothelial damage and its mechanism require investigation.

Purpose of the Study:

  • To investigate Azilsartan's efficacy in ameliorating ox-LDL-induced endothelial cell dysfunction.
  • To explore the underlying molecular mechanisms, focusing on Krüppel-like factor 2 (KLF2).

Main Methods:

  • An in vitro endothelial dysfunction model was created using human umbilical vascular endothelial cells (HUVECs) exposed to ox-LDL.
  • Gene and protein expression (LOX-1, eNOS, occludin, KLF2) and mediator production (MCP-1, CXCL1, NO) were analyzed.
  • Endothelial permeability and the role of KLF2 were assessed using FITC-dextran assays and KLF2 silencing.

Main Results:

  • Azilsartan significantly suppressed ox-LDL-induced increases in LOX-1, MCP-1, and CXCL-1.
  • It reversed ox-LDL-induced downregulation of eNOS and nitric oxide (NO) production.
  • Azilsartan treatment improved endothelial barrier function and occludin expression, effects dependent on KLF2, and increased KLF2 expression inhibited by ox-LDL.

Conclusions:

  • Azilsartan demonstrates a protective effect against ox-LDL-induced endothelial damage.
  • The mechanism involves the upregulation of KLF2, which subsequently improves endothelial function and barrier integrity.
Abstract

Keywords:
Azilsartanatherosclerosisendothelial dysfunctionox-LDL

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.1K
Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice07:36

Induction of Atherosclerotic Plaques Through Activation of Mineralocorticoid Receptors in Apolipoprotein E-deficient Mice

Published on: September 26, 2018

10.3K

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.0K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
1.9K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
89
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
970
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
645
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
306